Literature DB >> 18496263

Dilemmas in chronic/persistent pain management.

Warren A Katz1, Robert L Barkin.   

Abstract

The burden of chronic/persistent pain is substantial for the patient and society as a whole. Although a variety of pharmacologic treatments are available, chronic/persistent pain remains inadequately treated. Many pharmacologic treatment options provide analgesic efficacy for 4 to 6 hours, requiring multiple doses for continuous pain relief. The inconvenience of multiple doses may prevent many patients from achieving adequate pain relief. Other limitations to the current pharmacologic treatment options include gastrointestinal effects, cardiovascular effects, and organ toxicity, as well as fear of abuse or addiction. The purpose of this review is to highlight the burden of chronic/persistent pain in today's society and discuss the limitations of short-acting pharmacologic therapies used in the treatment of chronic/persistent pain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18496263     DOI: 10.1097/MJT.0b013e3181671c5a

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  8 in total

1.  An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UV(B)-inflamed and normal skin.

Authors:  Klaus Schaffler; Peter Reeh; W Rachel Duan; Andrea E Best; Ahmed A Othman; Connie R Faltynek; Charles Locke; Wolfram Nothaft
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

2.  Analgesia or addiction?: implications for morphine use after spinal cord injury.

Authors:  Sarah A Woller; Georgina L Moreno; Nigel Hart; Paul J Wellman; James W Grau; Michelle A Hook
Journal:  J Neurotrauma       Date:  2012-04-02       Impact factor: 5.269

Review 3.  The missing p in psychiatric training: why it is important to teach pain to psychiatrists.

Authors:  Igor Elman; Jon-Kar Zubieta; David Borsook
Journal:  Arch Gen Psychiatry       Date:  2011-01

4.  Efficacy and safety of sublingual fentanyl tablets for the management of breakthrough pain in patients with chronic musculoskeletal pain with neuropathic component: multicenter prospective study.

Authors:  Luz Cánovas-Martínez; José J Carceller-Ruiz; Pilar Díaz-Parada; Gustavo Illodo-Miramontes; Enrique Freire-Vila; Aurora De la Iglesia-López; Belén García Iglesias; Beatriz López-Ulloa; Enrique Domínguez-Suárez; Alberto Camba-Rodríguez
Journal:  Clin Drug Investig       Date:  2015-03       Impact factor: 2.859

5.  Combined use of pregabalin and memantine in fibromyalgia syndrome treatment: a novel analgesic and neuroprotective strategy?

Authors:  Jill M Recla; Constantine D Sarantopoulos
Journal:  Med Hypotheses       Date:  2009-04-10       Impact factor: 1.538

Review 6.  Conotoxin Interactions with α9α10-nAChRs: Is the α9α10-Nicotinic Acetylcholine Receptor an Important Therapeutic Target for Pain Management?

Authors:  Sarasa A Mohammadi; MacDonald J Christie
Journal:  Toxins (Basel)       Date:  2015-09-28       Impact factor: 4.546

7.  α9-nicotinic acetylcholine receptors contribute to the maintenance of chronic mechanical hyperalgesia, but not thermal or mechanical allodynia.

Authors:  Sarasa Mohammadi; Macdonald J Christie
Journal:  Mol Pain       Date:  2014-10-02       Impact factor: 3.395

Review 8.  Tramadol Extended-Release for the Management of Pain due to Osteoarthritis.

Authors:  Chiara Angeletti; Cristiana Guetti; Antonella Paladini; Giustino Varrassi
Journal:  ISRN Pain       Date:  2013-09-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.